^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD47 inhibitor

    Related drugs:
    8d
    A Study of IMM0306 in IgG4-Related Disease (clinicaltrials.gov)
    P2/3, N=125, Not yet recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
    New P2/3 trial
    |
    amouravfop alfa (IMM0306)
    21d
    ILLUMINE: Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN (clinicaltrials.gov)
    P3, N=780, Recruiting, Groupe Oncologie Radiotherapie Tete et Cou | Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2030 --> May 2030
    Enrollment open • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Idafang (ivonescimab) • ligufalimab (AK117)
    22d
    Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer) (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, University of California, San Diego | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • evorpacept (ALX148)
    1m
    ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, ALX Oncology Inc.
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • gemcitabine • paclitaxel • capecitabine • eribulin mesylate • vinorelbine tartrate • evorpacept (ALX148)
    1m
    C4971006: A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. (clinicaltrials.gov)
    P1/2, N=40, Terminated, Pfizer | N=30 --> 40 | Active, not recruiting --> Terminated; Business/Administrative decision to pursue other programs/assets within the oncology portfolio. Not due to any detected safety signals or requests from regulatory authorities.
    Enrollment change • Trial termination
    |
    Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm) • maplirpacept (TTI-622)
    1m
    LCB-1801-001: A phase I study of the mesothelin x cd47 antibody NI-1801, as single agent and in combination with anti-pd-1 antibody, or with paclitaxel alone in solid cancers or with anti-pd-1 and paclitaxel +/- bevacizumab in proc (2024-517752-35-00)
    P1, N=108, Recruiting, NovImmune S.A. | N=82 --> 108
    Enrollment change
    |
    Avastin (bevacizumab) • paclitaxel • NI-1801
    2ms
    HX009-II-02: Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma (clinicaltrials.gov)
    P1/2, N=48, Completed, Hangzhou Hanx Biopharmaceuticals, Ltd. | Recruiting --> Completed | N=99 --> 48 | Trial completion date: Dec 2026 --> Dec 2025 | Trial primary completion date: Dec 2025 --> Jun 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    HX-009
    2ms
    A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) (clinicaltrials.gov)
    P1, N=9, Terminated, Aurigene Discovery Technologies Limited | N=42 --> 9 | Trial completion date: Jan 2027 --> Feb 2026 | Recruiting --> Terminated | Trial primary completion date: Nov 2026 --> Feb 2026; Patient recruitment problems
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    AU7R-104 • XL114
    2ms
    Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=20, Completed, Hangzhou Hanx Biopharmaceuticals, Ltd. | Active, not recruiting --> Completed | N=210 --> 20
    Trial completion • Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    HX-009
    2ms
    A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome. (clinicaltrials.gov)
    P1, N=18, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase classification: P2 --> P1
    Phase classification
    |
    CRP (C-reactive protein)
    |
    danburstotug (IMC-001) • timdarpacept (IMM01)
    2ms
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=59, Active, not recruiting, Pfizer | Trial primary completion date: Apr 2026 --> Jul 2025
    Trial primary completion date
    |
    carfilzomib • dexamethasone • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    2ms
    A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome. (clinicaltrials.gov)
    P2, N=18, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | N=30 --> 18 | Trial completion date: Jun 2026 --> Oct 2026 | Trial primary completion date: Jun 2026 --> Oct 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CRP (C-reactive protein)
    |
    danburstotug (IMC-001) • timdarpacept (IMM01)